ରିସାଙ୍କିଜୁମାବ

ରିସାଙ୍କିଜୁମାବ
Monoclonal antibody
Type	Whole antibody
Source	Humanized
Target	interleukin 23A
Clinical data
Pronunciation	RIS an KIZ ue mab
Trade names	Skyrizi
Synonyms	BI-655066, ABBV-066, risankizumab-rzaa
AHFS/Drugs.com	monograph
MedlinePlus	a619035
data	EU EMA: yes; US DailyMed: Risankizumab;
Pregnancy; category	AU: B1 ; US: N (Not classified yet) ; ;
Routes of; administration	Subcutaneous injection
Legal status
Legal status	UK: POM (Prescription only) ; US: ℞-only ; EU: Rx-only ;
Chemical and physical data
Formula	C6476H9992N1720O2016S44
Molar mass	୧,୪୫,୬୧୧.୮୪ g·mol−1

ରିସାଙ୍କିଜୁମାବ, ଏକ ବେପାର ନାମ ସ୍କାଇରିଜି, ହେଉଛି ଏକ ଔଷଧ ଯାହା ମଧ୍ୟମରୁ ଗମ୍ଭୀର ଧରଣର ପ୍ଲେକ ସୋରିୟାସିସ୍ ରୋଗର ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ହୁଏ ।^[୪]ସାଧାରଣ ପୁଷ୍ଟୁଲାର ସୋରିଆସିସ୍, ଏରିଥ୍ରୋଡର୍ମିକ୍ ସୋରିଆସିସ୍ ଏବଂ ସୋରିଆଟିକ ଗଣ୍ଠି ପ୍ରଦାହ ରୋଗମାନଙ୍କରେ ମଧ୍ୟ ଏହା ବ୍ୟବ‌ହାର ହୋଇପାରେ ।^[୫]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଉର୍ଦ୍ଧ୍ୱ ଶ୍ୱାସନଳୀ ସଂକ୍ରମଣ, ମୁଣ୍ଡବିନ୍ଧା, ଥକାପଣ ଏବଂ ଇଞ୍ଜେକ୍ସନ ସ୍ଥାନରେ ଯନ୍ତ୍ରଣା ହୋଇପାରେ ।^[୨] ^[୬] ଏହା ଯୋଗୁ ଅନ୍ୟ ସଂକ୍ରମଣର ଆଶଙ୍କା ମଧ୍ୟ ବଢ଼ି ଯାଇଥାଏ ।^[୬] ଗର୍ଭାବସ୍ଥାରେ ଏହା ଗ୍ରହଣ କଲେ କ୍ଷତିର କୌଣସି ପ୍ରମାଣ ନଥିବାବେଳେ, ଏପରି ବ୍ୟବହାର ଭଲ ଭାବରେ ଅଧ୍ୟୟନ କରାଯାଇ ନାହିଁ ।^[୭] ଏହା ଏକ ମୋନୋକ୍ଲୋନାଲ ଆଣ୍ଟିବଡି ଯାହା ଇଣ୍ଟରଲ୍ୟୁକିନ୍ ୨୩ ଏ (IL-23A) ସ‌ହିତ ସଂଲଗ୍ନ ହୁଏ ଏବଂ ଅବରୋଧ କରେ ।^[୨] ^[୮]

୨୦୧୯ ମସିହାରେ ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଡାକ୍ତରୀ ବ୍ୟବହାର ପାଇଁ ରିସାଙ୍କିଜୁମାବ ଅନୁମୋଦିତ ହୋଇଥିଲା ।^[୬] ^[୨] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ୨୦୨୧ ସୁଦ୍ଧା ଏହାର ଏକ ମାତ୍ରା ପିଛା ମୂଲ୍ୟ ପ୍ରାୟ ୧୭,୮୦୦ ଡଲାର ରହିଛି ।^[୯] ଯୁକ୍ତରାଜ୍ୟରେ ଏହି ରାଶିର ମୂଲ୍ୟ ପ୍ରାୟ ୩,୩୦୦ପାଉଣ୍ଡ ଥିଲା । ^[୧୦]

ଆଧାର ସମ୍ପାଦନା

↑ ^୧.୦ ^୧.୧ "Risankizumab (Skyrizi) Use During Pregnancy". Drugs.com. 15 July 2019. Archived from the original on 28 October 2020. Retrieved 23 September 2020.
↑ ^୨.୦ ^୨.୧ ^୨.୨ ^୨.୩ "Skyrizi". Archived from the original on 25 October 2020. Retrieved 18 October 2021.
↑ "Skyrizi 75 mg solution for injection in pre-filled syringe - Summary of Product Characteristics (SmPC)". (emc). Archived from the original on 29 August 2021. Retrieved 23 September 2020.
↑ ^୪.୦ ^୪.୧ "Skyrizi- risankizumab-rzaa kit". DailyMed. 12 June 2020. Archived from the original on 29 August 2021. Retrieved 23 September 2020.
↑ "Japan Approves Risankizumab for Psoriasis & Psoriatic Arthritis". The Rheumatologist. 15 April 2019. Archived from the original on 24 June 2021. Retrieved 24 June 2021.
↑ ^୬.୦ ^୬.୧ ^୬.୨ "Risankizumab-rzaa Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 28 September 2021. Retrieved 18 October 2021.
↑ "Risankizumab (Skyrizi) Use During Pregnancy". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 28 October 2020. Retrieved 18 October 2021.
↑ Singh S, Kroe-Barrett RR, Canada KA, Zhu X, Sepulveda E, Wu H, He Y, Raymond EL, Ahlberg J, Frego LE, Amodeo LM, Catron KM, Presky DH, Hanke JH (July–August 2015). "Selective targeting of the IL23 pathway: Generation and characterization of a novel high-affinity humanized anti-IL23A antibody". mAbs. 7 (4): 778–91. doi:10.1080/19420862.2015.1032491. PMC 4622456. PMID 25905918. {{cite journal}}: Unknown parameter |displayauthors= ignored (|display-authors= suggested) (help)
↑ "Skyrizi Prices, Coupons & Patient Assistance Programs". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 30 September 2021. Retrieved 18 October 2021.
↑ BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 1326. ISBN 978-0-85711-369-6.{{cite book}}: CS1 maint: date format (link)

[Drugs.com_pregnancy-1] ୧.୦ ^୧.୧ "Risankizumab (Skyrizi) Use During Pregnancy". Drugs.com. 15 July 2019. Archived from the original on 28 October 2020. Retrieved 23 September 2020.

[EPAR2021-2] ୨.୦ ^୨.୧ ^୨.୨ ^୨.୩ "Skyrizi". Archived from the original on 25 October 2020. Retrieved 18 October 2021.

[Skyrizi_SmPC-3] "Skyrizi 75 mg solution for injection in pre-filled syringe - Summary of Product Characteristics (SmPC)". (emc). Archived from the original on 29 August 2021. Retrieved 23 September 2020.

[PI2021-4] ୪.୦ ^୪.୧ "Skyrizi- risankizumab-rzaa kit". DailyMed. 12 June 2020. Archived from the original on 29 August 2021. Retrieved 23 September 2020.

[5] "Japan Approves Risankizumab for Psoriasis & Psoriatic Arthritis". The Rheumatologist. 15 April 2019. Archived from the original on 24 June 2021. Retrieved 24 June 2021.

[AHFS2021-6] ୬.୦ ^୬.୧ ^୬.୨ "Risankizumab-rzaa Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 28 September 2021. Retrieved 18 October 2021.

[7] "Risankizumab (Skyrizi) Use During Pregnancy". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 28 October 2020. Retrieved 18 October 2021.

[8] Singh S, Kroe-Barrett RR, Canada KA, Zhu X, Sepulveda E, Wu H, He Y, Raymond EL, Ahlberg J, Frego LE, Amodeo LM, Catron KM, Presky DH, Hanke JH (July–August 2015). "Selective targeting of the IL23 pathway: Generation and characterization of a novel high-affinity humanized anti-IL23A antibody". mAbs. 7 (4): 778–91. doi:10.1080/19420862.2015.1032491. PMC 4622456. PMID 25905918. {{cite journal}}: Unknown parameter |displayauthors= ignored (|display-authors= suggested) (help)

[9] "Skyrizi Prices, Coupons & Patient Assistance Programs". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 30 September 2021. Retrieved 18 October 2021.

[BNF80-10] BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 1326. ISBN 978-0-85711-369-6.{{cite book}}: CS1 maint: date format (link)

[୪]

[୫]

[୧]

[୩]

[୨]

[୬]

[୭]

[୮]

[୯]

[୧୦]